enVVeno receives FDA not-approvable letter for VenoValve PMA

enVVeno Medical Corp

FDA issued not-approvable letter for VenoValve PMA, citing insufficient benefit-risk profile.
FDA raised concerns about bias without hemodynamic measurement and safety from open surgical procedure.
Company reviewing options including resubmission or appeal; continues to work with FDA.
VenoValve is lead product for severe deep chronic venous insufficiency; no approved effective treatments currently.
Company also developing non-surgical enVVe valve; expects to apply learnings for its IDE application.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.